Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 10/20 | 0.62 |
| ▸ | FLT1 known ✓ | P17948 | 5/20 | 0.62 |
| ▸ | KIT known ✓ | P10721 | 5/20 | 0.62 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 0.62 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.62 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.62 |
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.62 |
| ▸ | CSF1R | P07333 | 4/20 | 0.62 |
| ▸ | TYK2 | P29597 | 3/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | TXK | P42681 | 2/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724300 | 0.97 | BTK (0.79) | BTKKDRFLT1KITPDGFRA | |
| Hydrochloric Acid SCHEMBL159486 | 0.97 | BTK (0.77) | BTKKDRFLT1KITPDGFRA | |
| Hydrochloric Acid SCHEMBL935691 | 0.96 | BTK (0.76) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL725543 | 0.93 | BTK (0.67) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL15973689 | 0.87 | BTK (0.62) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL12575010 | 0.86 | BTK (1.00) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL17135511 | 0.84 | BTK (0.58) | BTKKDRFLT1KITPDGFRA | |
| Hydrochloric Acid SCHEMBL6125704 | 0.84 | BTK (0.56) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL29884143 | 0.84 | BTK (0.73) | BTKKDRFLT1KITPDGFRA | |
| SCHEMBL28843997 | 0.84 | BTK (0.73) | BTKKDRFLT1KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755394-A4 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070208023-A1 | Cancer Treatment Method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1755394-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1515955-A4 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208023-A1 | Cancer Treatment Method | TP53, TYMP, TOP2A | KDR 1918/4885FLT1 1956/4885KIT 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.